Switch to:
Also traded in: Austria, Germany, Mexico, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.02
SHPG's Cash-to-Debt is ranked lower than
99% of the 1056 Companies
in the Global Biotechnology industry.

( Industry Median: 73.06 vs. SHPG: 0.02 )
Ranked among companies with meaningful Cash-to-Debt only.
SHPG' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01  Med: 1.14 Max: No Debt
Current: 0.02
0.01
No Debt
Equity-to-Asset 0.55
SHPG's Equity-to-Asset is ranked lower than
67% of the 770 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. SHPG: 0.55 )
Ranked among companies with meaningful Equity-to-Asset only.
SHPG' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.25  Med: 0.55 Max: 0.85
Current: 0.55
0.25
0.85
Debt-to-Equity 0.50
SHPG's Debt-to-Equity is ranked lower than
69% of the 488 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. SHPG: 0.50 )
Ranked among companies with meaningful Debt-to-Equity only.
SHPG' s Debt-to-Equity Range Over the Past 10 Years
Min: 0  Med: 0.29 Max: 1.12
Current: 0.5
0
1.12
Debt-to-EBITDA 3.49
SHPG's Debt-to-EBITDA is ranked lower than
76% of the 213 Companies
in the Global Biotechnology industry.

( Industry Median: 1.97 vs. SHPG: 3.49 )
Ranked among companies with meaningful Debt-to-EBITDA only.
SHPG' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.23  Med: 1.02 Max: 9.02
Current: 3.49
0.23
9.02
Interest Coverage 6.59
SHPG's Interest Coverage is ranked lower than
92% of the 521 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. SHPG: 6.59 )
Ranked among companies with meaningful Interest Coverage only.
SHPG' s Interest Coverage Range Over the Past 10 Years
Min: 3.85  Med: 25.3 Max: 63.3
Current: 6.59
3.85
63.3
Piotroski F-Score: 7
Altman Z-Score: 1.65
Beneish M-Score: -2.45
WACC vs ROIC
7.63%
14.30%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 24.20
SHPG's Operating Margin % is ranked higher than
85% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -98.02 vs. SHPG: 24.20 )
Ranked among companies with meaningful Operating Margin % only.
SHPG' s Operating Margin % Range Over the Past 10 Years
Min: 17.13  Med: 23.3 Max: 34.02
Current: 24.2
17.13
34.02
Net Margin % 28.83
SHPG's Net Margin % is ranked higher than
93% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -88.19 vs. SHPG: 28.83 )
Ranked among companies with meaningful Net Margin % only.
SHPG' s Net Margin % Range Over the Past 10 Years
Min: 2.87  Med: 16.7 Max: 56.55
Current: 28.83
2.87
56.55
ROE % 13.06
SHPG's ROE % is ranked higher than
88% of the 969 Companies
in the Global Biotechnology industry.

( Industry Median: -40.23 vs. SHPG: 13.06 )
Ranked among companies with meaningful ROE % only.
SHPG' s ROE % Range Over the Past 10 Years
Min: 1.76  Med: 24.12 Max: 110.67
Current: 13.06
1.76
110.67
ROA % 6.47
SHPG's ROA % is ranked higher than
86% of the 1062 Companies
in the Global Biotechnology industry.

( Industry Median: -32.55 vs. SHPG: 6.47 )
Ranked among companies with meaningful ROA % only.
SHPG' s ROA % Range Over the Past 10 Years
Min: 0.81  Med: 10.9 Max: 50.36
Current: 6.47
0.81
50.36
ROC (Joel Greenblatt) % 29.26
SHPG's ROC (Joel Greenblatt) % is ranked higher than
87% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -430.94 vs. SHPG: 29.26 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
SHPG' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 20.13  Med: 143.44 Max: 420.2
Current: 29.26
20.13
420.2
3-Year Revenue Growth Rate 24.00
SHPG's 3-Year Revenue Growth Rate is ranked higher than
76% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. SHPG: 24.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
SHPG' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -0.8  Med: 14.1 Max: 37.3
Current: 24
-0.8
37.3
3-Year EBITDA Growth Rate -1.60
SHPG's 3-Year EBITDA Growth Rate is ranked lower than
58% of the 722 Companies
in the Global Biotechnology industry.

( Industry Median: 3.10 vs. SHPG: -1.60 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
SHPG' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 7.8 Max: 53.5
Current: -1.6
0
53.5
3-Year EPS without NRI Growth Rate -0.70
SHPG's 3-Year EPS without NRI Growth Rate is ranked lower than
57% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. SHPG: -0.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
SHPG' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 12.7 Max: 90.1
Current: -0.7
0
90.1
GuruFocus has detected 4 Warning Signs with Shire PLC SHPG.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» SHPG's 30-Y Financials

Financials (Next Earnings Date: 2018-08-03)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2017

SHPG Guru Trades in Q2 2017

Pioneer Investments 67,699 sh (+331.23%)
Steven Cohen 267,300 sh (+84.66%)
Larry Robbins 1,722,977 sh (+69.67%)
Lee Ainslie 1,942,087 sh (+19.92%)
Mario Gabelli 6,904 sh (+15.22%)
Jim Simons 365,277 sh (+14.44%)
Scott Black 13,350 sh (+10.51%)
John Buckingham 29,879 sh (+8.77%)
Leon Cooperman 500,207 sh (+2.65%)
Andreas Halvorsen 797,053 sh (+1.44%)
Tweedy Browne Global Value 6,803 sh (unchged)
Jeff Auxier 1,705 sh (unchged)
John Paulson 125,000 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 82,128 sh (unchged)
John Hussman Sold Out
Jana Partners Sold Out
Steve Mandel Sold Out
Third Avenue Management 69,324 sh (-0.26%)
Tweedy Browne 32,874 sh (-5.13%)
John Paulson 3,481,600 sh (-12.92%)
Mairs and Power 15,981 sh (-15.83%)
Murray Stahl 5,000 sh (-16.67%)
Ken Fisher 55,800 sh (-61.38%)
» More
Q3 2017

SHPG Guru Trades in Q3 2017

First Eagle Investment 163 sh (New)
Daniel Loeb 1,200,000 sh (New)
George Soros 90,000 sh (New)
Larry Robbins 5,869,138 sh (+240.64%)
Leon Cooperman 653,977 sh (+30.74%)
Pioneer Investments 85,399 sh (+26.15%)
Mario Gabelli 7,830 sh (+13.41%)
John Buckingham 30,761 sh (+2.95%)
Ken Fisher 57,419 sh (+2.90%)
Lee Ainslie 1,971,791 sh (+1.53%)
Tweedy Browne Global Value 6,803 sh (unchged)
Jeff Auxier 1,705 sh (unchged)
Jim Simons Sold Out
Murray Stahl Sold Out
Eaton Vance Worldwide Health Sciences Fund Sold Out
Scott Black 13,340 sh (-0.07%)
Tweedy Browne 32,558 sh (-0.96%)
John Paulson 3,153,400 sh (-9.43%)
Mairs and Power 13,036 sh (-18.43%)
Steven Cohen 209,300 sh (-21.70%)
Andreas Halvorsen 520,685 sh (-34.67%)
Third Avenue Management 1,491 sh (-97.85%)
» More
Q4 2017

SHPG Guru Trades in Q4 2017

Richard Snow 218,484 sh (New)
Steven Cohen 556,880 sh (+166.07%)
Leon Cooperman 980,356 sh (+49.91%)
First Eagle Investment 163 sh (unchged)
Jeff Auxier 1,705 sh (unchged)
Tweedy Browne Global Value Sold Out
Scott Black Sold Out
Third Avenue Management Sold Out
Andreas Halvorsen Sold Out
Daniel Loeb Sold Out
George Soros Sold Out
Tweedy Browne Sold Out
Martin Whitman Sold Out
Spiros Segalas Sold Out
Larry Robbins 5,738,610 sh (-2.22%)
John Paulson 3,052,200 sh (-3.21%)
Ken Fisher 55,073 sh (-4.09%)
John Buckingham 29,128 sh (-5.31%)
Mario Gabelli 7,293 sh (-6.86%)
Lee Ainslie 1,662,637 sh (-15.68%)
Pioneer Investments 50,700 sh (-40.63%)
Mairs and Power 3,868 sh (-70.33%)
» More
Q1 2018

SHPG Guru Trades in Q1 2018

Chris Davis 1,860,234 sh (New)
Jim Simons 188,677 sh (New)
Richard Snow 466,549 sh (+113.54%)
John Buckingham 31,930 sh (+9.62%)
Pioneer Investments 55,249 sh (+8.97%)
Larry Robbins 6,001,684 sh (+4.58%)
Lee Ainslie 1,713,431 sh (+3.06%)
Ken Fisher 55,678 sh (+1.10%)
Jeff Auxier 1,705 sh (unchged)
First Eagle Investment Sold Out
Mario Gabelli 7,264 sh (-0.40%)
John Paulson 2,952,200 sh (-3.28%)
Mairs and Power 3,659 sh (-5.40%)
Leon Cooperman 411,872 sh (-57.99%)
Steven Cohen 84,000 sh (-84.92%)
» More
» Details

Insider Trades

Latest Guru Trades with SHPG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Paulson 2018-03-31 Reduce -3.28%0.3%$125.03 - $159.21 $ 160.0516%2,952,200
Chris Davis 2018-03-31 New Buy1.2%$125.03 - $159.21 $ 160.0516%1,860,234
Leon Cooperman 2018-03-31 Reduce -57.99%3.31%$125.03 - $159.21 $ 160.0516%411,872
Ken Fisher 2018-03-31 Add 1.10%$125.03 - $159.21 $ 160.0516%55,678
Mario Gabelli 2018-03-31 Reduce -0.40%$125.03 - $159.21 $ 160.0516%7,264
First Eagle Investment 2018-03-31 Sold Out $125.03 - $159.21 $ 160.0516%0
John Paulson 2017-12-31 Reduce -3.21%0.28%$138.24 - $157.65 $ 160.058%3,052,200
Leon Cooperman 2017-12-31 Add 49.91%1.9%$138.24 - $157.65 $ 160.058%980,356
Ken Fisher 2017-12-31 Reduce -4.09%$138.24 - $157.65 $ 160.058%55,073
Mario Gabelli 2017-12-31 Reduce -6.86%$138.24 - $157.65 $ 160.058%7,293
George Soros 2017-12-31 Sold Out 0.41%$138.24 - $157.65 $ 160.058%0
Third Avenue Management 2017-12-31 Sold Out 0.01%$138.24 - $157.65 $ 160.058%0
Tweedy Browne 2017-12-31 Sold Out 0.14%$138.24 - $157.65 $ 160.058%0
Martin Whitman 2017-10-31 Sold Out 1.64%$138.24 - $167.2 $ 160.056%0
John Paulson 2017-09-30 Reduce -9.43%0.74%$140.85 - $169.8 $ 160.052%3,153,400
Leon Cooperman 2017-09-30 Add 30.74%0.91%$140.85 - $169.8 $ 160.052%653,977
George Soros 2017-09-30 New Buy0.41%$140.85 - $169.8 $ 160.052%90,000
Ken Fisher 2017-09-30 Add 2.90%$140.85 - $169.8 $ 160.052%57,419
Tweedy Browne 2017-09-30 Reduce -0.96%$140.85 - $169.8 $ 160.052%32,558
Mario Gabelli 2017-09-30 Add 13.41%$140.85 - $169.8 $ 160.052%7,830
Third Avenue Management 2017-09-30 Reduce -97.85%0.5%$140.85 - $169.8 $ 160.052%1,491
First Eagle Investment 2017-09-30 New Buy$140.85 - $169.8 $ 160.052%163
Martin Whitman 2017-07-31 Add 67.82%0.66%$160.22 - $190 $ 160.05-7%103,438
John Paulson 2017-06-30 Reduce -12.92%1.2%$162.35 - $190 $ 160.05-8%3,481,600
Leon Cooperman 2017-06-30 Add 2.65%0.09%$162.35 - $190 $ 160.05-8%500,207
Third Avenue Management 2017-06-30 Reduce -0.26%$162.35 - $190 $ 160.05-8%69,324
Ken Fisher 2017-06-30 Reduce -61.38%0.02%$162.35 - $190 $ 160.05-8%55,800
Tweedy Browne 2017-06-30 Reduce -5.13%0.01%$162.35 - $190 $ 160.05-8%32,874
Mario Gabelli 2017-06-30 Add 15.22%$162.35 - $190 $ 160.05-8%6,904
Steve Mandel 2017-06-30 Sold Out 1.57%$162.35 - $190 $ 160.05-8%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:BIIB, ASX:CSL, NAS:VRTX, NAS:REGN, XKRX:068270, XKRX:207940, NAS:CELG, NAS:ALXN, HKSE:01177, XMCE:GRF.P, NAS:BMRN, XBRU:UCB, NAS:NKTR, OCSE:NZYM B, NAS:INCY, OCSE:GEN, NAS:BIVV, HKSE:02269, NAS:JUNO, NAS:ALNY » details
Traded in other countries:SHPG.Austria, S7E.Germany, SHPG N.Mexico, SHP.UK, SHPGF.USA,
Headquarter Location:Ireland
Shire PLC is a biotechnology company focused mainly in the research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines for patients with rare diseases and other select conditions.

Shire is a diversified, Ireland-based specialty drug firm. Shire has grown primarily through mergers and acquisitions, including the Transkaryotic Therapies acquisition in 2005, which established its genetic disease business with Replagal and Elaprase, and the merger with New River in 2007, which brought full rights to neuroscience drug Vyvanse. Shire completed the acquisition of ViroPharma (genetic diseases) in 2014, NPS Pharma (internal medicine) in 2015, and Baxalta (hematology, immunology, and oncology) and Dyax (genetic diseases) in 2016.

Guru Investment Theses on Shire PLC

Keeley All Cap Value Fund Comments on Shire - Jan 27, 2017

Given the volatile Health Care sector this quarter, the Fund’s position in Shire (NASDAQ:SHPG) was also a leading detractor. Headline risk regarding potential pharmaceutical price controls has impacted the stock. With continued synergies from its acquisition of Baxalta and trading at 11x earnings, we feel the stock remains quite attractive.



From the Keeley All Cap Value Fund fourth quarter 2016 commentary.







Check out Keeley Asset Management Corp latest stock trades

Top Ranked Articles about Shire PLC

Shire launches screen responsibly, an eyelove® initiative dedicated to prioritizing eye health in a screen-saturated world
New Research: Key Drivers of Growth for Helen of Troy, Macro Bank, American Software, Shire plc, KB Financial Group, and Odonate Therapeutics — Factors of Influence, Major Initiatives and Sustained Production
Takeda-Shire Merger: A Case of Cutting Fat or Slicing to the Bone? Takeda promises to slash the R&D budget without undermining the pipeline
We have dedicated two recent research notes to discussing the ongoing merger of Japanese pharma giant Takeda (TSE:4502) and the even bigger Shire (NASDAQ:SHPG). In our first entry, we discussed the abortive attempt by Allergan (NYSE:AGN) to make a play for Shire in opposition to Takeda. Our second, focused on the significant challenges still ahead for Takeda, including justifying the leveraged purchase of the Hiberno-American biopharmaceutical company to skeptical shareholders. Read more...
Shire Recognizes MPS Awareness Day 2018 with Digital Campaign and Global Events Focused on Increasing Diseases Awareness
Chris Davis’ Top 3 Buys of the 1st Quarter Guru releases quarterly portfolio
Chris Davis (Trades, Portfolio), portfolio manager of Davis Financial Fund, disclosed on Monday he initiated 13 new positions during the first quarter. The guru’s three top new positions are Shire PLC (NASDAQ:SHPG), Bank of N.T. Butterfield & Son Ltd. (NYSE:NTB) and iQiyi Inc. (NASDAQ:IQ). Read more...
Caladrius Biosciences Reports 2018 First Quarter Financial Results
Takeda Closes In on Shire, but It's Not a Done Deal Yet The massive buyout still faces significant hurdles
After rather swift negotiations, Japanese pharmaceutical company Takeda (TSE:4502) has come to terms with Shire (NASDAQ:SHPG), a major biopharmaceutical company (and actually bigger than Takeda itself). For months, Shire has been at the top of numerous industry lists as a potential buyout target, so it was not terribly surprising when Takeda put it into play in April. Read more...
Francisco Garcia Paramés’ Top 4 Buys in 1st Quarter Self-taught follower of Buffett’s investing approach discloses quarterly portfolio
Francisco Garcia Paramés, chief investment officer of Cobas Asset Management, disclosed on Friday that he added eight new positions to his portfolio during the first quarter. The top 4 buys based on portfolio impact are Ensco PLC (NYSE:ESV), OCI NV (XAMS:OCI), Shire PLC (NASDAQ:SHPG)(LSE:SHP) and KT Corp. (NYSE:KT). Read more...
Strong Revenue and Earnings: CVS Health, Rush These companies have boosted their EPS over a 5-year period
According to the GuruFocus All-In-One Screener, the following companies have grown their revenues and earnings over the past several years. Read more...
Why Did Allergan Abandon the Shire Hunt? After moving to beat Takeda’s offer, the pharmaceutical company bailed almost immediately
When Takeda (TSE:4502) put Shire (NASDAQ:SHPG) into play a couple weeks ago, it looked to be the beginning of a serious hunt for the major biotech company. Takeda offered $62.5 billion for Shire, which had a pre-offer market cap of about $40 billion. Read more...

Ratios

vs
industry
vs
history
PE Ratio 10.95
SHPG's PE Ratio is ranked higher than
87% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 29.83 vs. SHPG: 10.95 )
Ranked among companies with meaningful PE Ratio only.
SHPG' s PE Ratio Range Over the Past 10 Years
Min: 8.24  Med: 25.87 Max: 161.29
Current: 10.95
8.24
161.29
Forward PE Ratio 10.55
SHPG's Forward PE Ratio is ranked higher than
94% of the 71 Companies
in the Global Biotechnology industry.

( Industry Median: 24.45 vs. SHPG: 10.55 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 10.95
SHPG's PE Ratio without NRI is ranked higher than
89% of the 255 Companies
in the Global Biotechnology industry.

( Industry Median: 30.45 vs. SHPG: 10.95 )
Ranked among companies with meaningful PE Ratio without NRI only.
SHPG' s PE Ratio without NRI Range Over the Past 10 Years
Min: 8.24  Med: 24.52 Max: 90.18
Current: 10.95
8.24
90.18
Price-to-Owner-Earnings 14.99
SHPG's Price-to-Owner-Earnings is ranked higher than
75% of the 148 Companies
in the Global Biotechnology industry.

( Industry Median: 36.07 vs. SHPG: 14.99 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
SHPG' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 11.27  Med: 24.49 Max: 213.44
Current: 14.99
11.27
213.44
PB Ratio 1.34
SHPG's PB Ratio is ranked higher than
92% of the 954 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. SHPG: 1.34 )
Ranked among companies with meaningful PB Ratio only.
SHPG' s PB Ratio Range Over the Past 10 Years
Min: 1.01  Med: 5.34 Max: 14.23
Current: 1.34
1.01
14.23
PS Ratio 3.18
SHPG's PS Ratio is ranked higher than
84% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. SHPG: 3.18 )
Ranked among companies with meaningful PS Ratio only.
SHPG' s PS Ratio Range Over the Past 10 Years
Min: 2.36  Med: 4.5 Max: 9.27
Current: 3.18
2.36
9.27
Price-to-Free-Cash-Flow 11.89
SHPG's Price-to-Free-Cash-Flow is ranked higher than
82% of the 128 Companies
in the Global Biotechnology industry.

( Industry Median: 33.20 vs. SHPG: 11.89 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
SHPG' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 8.96  Med: 23.97 Max: 2070
Current: 11.89
8.96
2070
Price-to-Operating-Cash-Flow 10.03
SHPG's Price-to-Operating-Cash-Flow is ranked higher than
86% of the 196 Companies
in the Global Biotechnology industry.

( Industry Median: 30.32 vs. SHPG: 10.03 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
SHPG' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 7.55  Med: 17.79 Max: 99.75
Current: 10.03
7.55
99.75
EV-to-EBIT 24.65
SHPG's EV-to-EBIT is ranked higher than
53% of the 262 Companies
in the Global Biotechnology industry.

( Industry Median: 24.43 vs. SHPG: 24.65 )
Ranked among companies with meaningful EV-to-EBIT only.
SHPG' s EV-to-EBIT Range Over the Past 10 Years
Min: -10.1  Med: 19.35 Max: 173.7
Current: 24.65
-10.1
173.7
EV-to-EBITDA 12.98
SHPG's EV-to-EBITDA is ranked higher than
71% of the 287 Companies
in the Global Biotechnology industry.

( Industry Median: 21.70 vs. SHPG: 12.98 )
Ranked among companies with meaningful EV-to-EBITDA only.
SHPG' s EV-to-EBITDA Range Over the Past 10 Years
Min: -11.6  Med: 14.15 Max: 53.3
Current: 12.98
-11.6
53.3
EV-to-Revenue 4.33
SHPG's EV-to-Revenue is ranked higher than
79% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: 13.46 vs. SHPG: 4.33 )
Ranked among companies with meaningful EV-to-Revenue only.
SHPG' s EV-to-Revenue Range Over the Past 10 Years
Min: 2.8  Med: 4.8 Max: 10
Current: 4.33
2.8
10
PEG Ratio 0.70
SHPG's PEG Ratio is ranked higher than
90% of the 105 Companies
in the Global Biotechnology industry.

( Industry Median: 2.48 vs. SHPG: 0.70 )
Ranked among companies with meaningful PEG Ratio only.
SHPG' s PEG Ratio Range Over the Past 10 Years
Min: 0.47  Med: 1.08 Max: 114.2
Current: 0.7
0.47
114.2
Shiller PE Ratio 28.05
SHPG's Shiller PE Ratio is ranked higher than
82% of the 79 Companies
in the Global Biotechnology industry.

( Industry Median: 44.16 vs. SHPG: 28.05 )
Ranked among companies with meaningful Shiller PE Ratio only.
SHPG' s Shiller PE Ratio Range Over the Past 10 Years
Min: 21.14  Med: 100.95 Max: 1407
Current: 28.05
21.14
1407
Current Ratio 1.14
SHPG's Current Ratio is ranked lower than
88% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 4.21 vs. SHPG: 1.14 )
Ranked among companies with meaningful Current Ratio only.
SHPG' s Current Ratio Range Over the Past 10 Years
Min: 0.52  Med: 1.54 Max: 7.43
Current: 1.14
0.52
7.43
Quick Ratio 0.66
SHPG's Quick Ratio is ranked lower than
92% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 3.92 vs. SHPG: 0.66 )
Ranked among companies with meaningful Quick Ratio only.
SHPG' s Quick Ratio Range Over the Past 10 Years
Min: 0.4  Med: 1.37 Max: 7.07
Current: 0.66
0.4
7.07
Days Inventory 275.61
SHPG's Days Inventory is ranked lower than
82% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: 126.17 vs. SHPG: 275.61 )
Ranked among companies with meaningful Days Inventory only.
SHPG' s Days Inventory Range Over the Past 10 Years
Min: 54.84  Med: 167.67 Max: 276.29
Current: 275.61
54.84
276.29
Days Sales Outstanding 71.45
SHPG's Days Sales Outstanding is ranked lower than
54% of the 656 Companies
in the Global Biotechnology industry.

( Industry Median: 64.11 vs. SHPG: 71.45 )
Ranked among companies with meaningful Days Sales Outstanding only.
SHPG' s Days Sales Outstanding Range Over the Past 10 Years
Min: 46.51  Med: 68.33 Max: 83.8
Current: 71.45
46.51
83.8
Days Payable 73.89
SHPG's Days Payable is ranked lower than
99.99% of the 456 Companies
in the Global Biotechnology industry.

( Industry Median: 62.86 vs. SHPG: 73.89 )
Ranked among companies with meaningful Days Payable only.
SHPG' s Days Payable Range Over the Past 10 Years
Min: 71.02  Med: 101.28 Max: 166.27
Current: 73.89
71.02
166.27

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 0.66
SHPG's Dividend Yield % is ranked lower than
62% of the 229 Companies
in the Global Biotechnology industry.

( Industry Median: 1.12 vs. SHPG: 0.66 )
Ranked among companies with meaningful Dividend Yield % only.
SHPG' s Dividend Yield % Range Over the Past 10 Years
Min: 0.23  Med: 0.43 Max: 0.85
Current: 0.66
0.23
0.85
Dividend Payout Ratio 0.07
SHPG's Dividend Payout Ratio is ranked higher than
99% of the 135 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. SHPG: 0.07 )
Ranked among companies with meaningful Dividend Payout Ratio only.
SHPG' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.04  Med: 0.1 Max: 0.39
Current: 0.07
0.04
0.39
3-Year Dividend Growth Rate 19.90
SHPG's 3-Year Dividend Growth Rate is ranked higher than
74% of the 88 Companies
in the Global Biotechnology industry.

( Industry Median: 7.00 vs. SHPG: 19.90 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
SHPG' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 14.3 Max: 57.8
Current: 19.9
0
57.8
Forward Dividend Yield % 0.65
SHPG's Forward Dividend Yield % is ranked higher than
55% of the 213 Companies
in the Global Biotechnology industry.

( Industry Median: 1.09 vs. SHPG: 0.65 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 1.93
SHPG's 5-Year Yield-on-Cost % is ranked higher than
65% of the 308 Companies
in the Global Biotechnology industry.

( Industry Median: 1.56 vs. SHPG: 1.93 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
SHPG' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.67  Med: 1.26 Max: 2.48
Current: 1.93
0.67
2.48
3-Year Average Share Buyback Ratio -15.50
SHPG's 3-Year Average Share Buyback Ratio is ranked lower than
55% of the 768 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. SHPG: -15.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
SHPG' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -28.8  Med: -1.9 Max: 7.1
Current: -15.5
-28.8
7.1

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 0.80
SHPG's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
92% of the 179 Companies
in the Global Biotechnology industry.

( Industry Median: 3.54 vs. SHPG: 0.80 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
SHPG' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.72  Med: 2.07 Max: 5.1
Current: 0.8
0.72
5.1
Price-to-Median-PS-Value 0.70
SHPG's Price-to-Median-PS-Value is ranked higher than
79% of the 614 Companies
in the Global Biotechnology industry.

( Industry Median: 1.00 vs. SHPG: 0.70 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
SHPG' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.63  Med: 0.97 Max: 2.78
Current: 0.7
0.63
2.78
Price-to-Peter-Lynch-Fair-Value 0.80
SHPG's Price-to-Peter-Lynch-Fair-Value is ranked higher than
90% of the 63 Companies
in the Global Biotechnology industry.

( Industry Median: 1.49 vs. SHPG: 0.80 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
SHPG' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.54  Med: 1.07 Max: 5.85
Current: 0.8
0.54
5.85
Earnings Yield (Greenblatt) % 4.01
SHPG's Earnings Yield (Greenblatt) % is ranked higher than
88% of the 1060 Companies
in the Global Biotechnology industry.

( Industry Median: -6.86 vs. SHPG: 4.01 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
SHPG' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -16.6  Med: 4.6 Max: 8.4
Current: 4.01
-16.6
8.4
Forward Rate of Return (Yacktman) % 19.84
SHPG's Forward Rate of Return (Yacktman) % is ranked higher than
57% of the 135 Companies
in the Global Biotechnology industry.

( Industry Median: 12.87 vs. SHPG: 19.84 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
SHPG' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -0.2  Med: 21.6 Max: 23.6
Current: 19.84
-0.2
23.6

More Statistics

Revenue (TTM) (Mil) $15,354.00
EPS (TTM) $ 14.58
Beta1.45
Volatility27.68%
52-Week Range $123.73 - 177.51
Shares Outstanding (Mil)304.66 (ADR)

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 15,451 15,923 17,106
EBIT (Mil $) 5,193 5,778 7,213
EBITDA (Mil $) 6,982 7,520 8,693
EPS ($) 8.49 10.25 12.15
EPS without NRI ($) 8.49 10.25 12.15
EPS Growth Rate
(Future 3Y To 5Y Estimate)
3.49%
Dividends per Share ($) 1.11 1.23 1.46

Piotroski F-Score Details

Piotroski F-Score: 77
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}